Supernus Pharmaceuticals, Inc. (SUPN) — Analysis Summary
Supernus Pharmaceuticals, Inc. (SUPN) has a market cap of $2.55B with year-over-year revenue growth of +8.6%. Net margin stands at -5.4%. The stock trades at a P/E ratio of -87.7.
Key Takeaways
- Revenue changed +8.6% year-over-year
- Net margin of -5.4%
- P/E ratio of -87.7
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SUPN posted revenue growth of +8.6% and trades at a P/E of -87.7.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.